Late Gadolinium Enhancement and the Risk for Ventricular Arrhythmias or Sudden Death in Dilated Cardiomyopathy: Systematic Review and Meta-Analysis

JACC: Heart Failure

Volumn 5, Issue 1, 2017, Pages 28-38

  Di Marco, Andrea ^a   Anguera, Ignasi ^a   Schmitt, Matthias ^b   Klem, Igor ^c   Neilan, Thomas ^d   White, James A ^e   Sramko, Marek ^f   Masci, Pier Giorgio ^g   Barison, Andrea ^h   Mckenna, Peter ⁱ   Mordi, Ify ^j   Haugaa, Kristina H ^k   Leyva, Francisco ^l   Rodriguez Capitán, Jorge ^m   Satoh, Hiroshi ⁿ   Nabeta, Takeru ^o   Dallaglio, Paolo Domenico ^a   Campbell, Niall G ^b   Sabaté, Xavier ^a   Cequier, Ángel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^f INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

ⁱ FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^m Hospital Antequera   (Spain)

ⁿ HAMAMATSU UNIVERSITY HOSPITAL   (Japan)

^o KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

cardiac magnetic resonance; dilated cardiomyopathy; late gadolinium enhancement; sudden death; ventricular arrhythmias

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GADOLINIUM; CONTRAST MEDIUM;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; DELAYED DIAGNOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; META ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; NEWCASTLE-OTTAWA SCALE; OBSERVATIONAL STUDY; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; COMPLICATION; DIAGNOSTIC IMAGING; HEART ARRHYTHMIA; NUCLEAR MAGNETIC RESONANCE IMAGING;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, DILATED; CONTRAST MEDIA; DEATH, SUDDEN, CARDIAC; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 85007552187     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.09.017     Document Type: Article

References (51)

1. 1 Buxton, A.E., Ellison, K.E., Lorvidhaya, P., Ziv, O., Left ventricular ejection fraction for sudden death risk stratification and guiding implantable cardioverter-defibrillators implantation. J Cardiovasc Pharmacol 55 (2010), 450–455.
2. 2 Kadish, A., Dyer, A., Daubert, J.P., et al., for the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350 (2004), 2151–2158.
3. 3 Køber, L., Thune, J.J., Nielsen, J.C., et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375 (2016), 1221–1230.
4. 4 Horowitz, L., Josephson, M., Harken, A., Epicardial and endocardial activation during sustained ventricular tachycardia in man. Circulation 61 (1980), 1227–1238.
5. 5 Iles, L.M., Ellims, A.H., Llewellyn, H., et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging 16 (2015), 14–22.
6. 6 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., for the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
7. 7 Higgins, J.P.T., Altman, D.G., Chapter 8: assessing risk of bias in included studies. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions, 2008, Cochrane Collaboration, Copenhagen, Denmark.
8. 8 Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed November 1, 2016.
9. 9 Sweeting, M.J., Sutton, A.J., Lambert, P.C., What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004), 1351–1375.
10. 10 Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
11. 11 Peters, J.L., Sutton, A.J., Jones, D.R., Abrams, K.R., Rushton, L., Comparison of two methods to detect publication bias in meta-analysis. JAMA 295 (2006), 676–680.
12. 12 Lehrke, S., Lossnitzer, D., Schöb, M., et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97 (2011), 727–732.
13. 13 Gao, P., Yee, R., Gula, L., et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ Cardiovasc Imaging 5 (2012), 448–456.
14. 14 Assomull, R.G., Prasad, S.K., Lyne, J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 (2006), 1977–1985.
15. 15 Gulati, A., Jabbour, A., Ismail, T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
16. 16 Almehmadi, F., Joncas, S.X., Nevis, I., et al. Prevalence of myocardial fibrosis patterns in patients with systolic dysfunction: prognostic significance for the prediction of sudden cardiac arrest or appropriate implantable cardiac defibrillator therapy. Circ Cardiovasc Imaging 7 (2014), 593–600.
17. 17 Buss, S.J., Breuninger, K., Lehrke, S., et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 16 (2015), 307–315.
18. 18 Wu, K.C., Weiss, R.G., Thiemann, D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008), 2414–2421.
19. 19 Kono, A.K., Ishii, K., Kumagai, H., Taniguchi, Y., Kajiya, T., Sugimura, K., Late gadolinium enhancement on cardiac magnetic resonance imaging: is it associated with a higher incidence of nonsustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy?. Jpn J Radiol 28 (2010), 355–361.
20. 20 Yokokawa, M., Tada, H., Koyama, K., et al. The characteristics and distribution of the scar tissue predict ventricular tachycardia in patients with advanced heart failure. Pacing Clin Electrophysiol 32 (2009), 314–322.
21. 21 Looi, J.L., Edwards, C., Armstrong, G.P., et al. Characteristics and prognostic importance of myocardial fibrosis in patients with dilated cardiomyopathy assessed by contrast-enhanced cardiac magnetic resonance imaging. Clin Med Insights Cardiol 4 (2010), 129–134.
22. 22 Iles, L., Pfluger, H., Lefkovits, L., et al. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 57 (2011), 821–828.
23. 23 Fernández-Armenta, J., Berruezo, A., Mont, L., et al. Use of myocardial scar characterization to predict ventricular arrhythmia in cardiac resynchronization therapy. Europace 14 (2012), 1578–1586.
24. 24 Klem, I., Weinsaft, J.W., Bahnson, T.D., et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol 60 (2012), 408–420.
25. 25 Leyva, F., Taylor, R.J., Foley, P.W., et al. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 60 (2012), 1659–1667.
26. 26 Masci, P.G., Barison, A., Aquaro, G.D., et al. Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy. Int J Cardiol 157 (2012), 43–47.
27. 27 Müller, K.A., Müller, I., Kramer, U., et al. Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study. PLoS One, 8, 2013, e57077.
28. 28 Neilan, T.G., Coelho-Filho, O.R., Danik, S.B., et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. J Am Coll Cardiol Img 6 (2013), 944–954.
29. 29 Šramko, M., Kubánek, M., Tintěra, J., et al. Utility of combination of cardiac magnetic resonance imaging and high-sensitivity cardiac troponin T assay in diagnosis of inflammatory cardiomyopathy. Am J Cardiol 111 (2013), 258–264.
30. 123I-BMIPP scintigraphy with cardiac magnetic resonance in patients with dilated cardiomyopathy. J Card Fail 19 (2013), 445–453.
31. 31 Hasselberg, N.E., Edvardsen, T., Petri, H., et al. Risk prediction of ventricular arrhythmias and myocardial function in lamin A/C mutation positive subjects. Europace 16 (2014), 563–571.
32. 32 Machii, M., Satoh, H., Shiraki, K., et al. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome. Magn Reson Imaging 32 (2014), 118–124.
33. 33 Masci, P.G., Doulaptsis, C., Bertella, E., et al. Incremental prognostic value of myocardial fibrosis in patients with non-ischemic cardiomyopathy without congestive heart failure. Circ Heart Fail 7 (2014), 448–456.
34. 34 Mordi, I., Jhund, P.S., Gardner, R.S., et al. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. J Am Coll Cardiol Img 7 (2014), 561–569.
35. 35 Nabeta, T., Inomata, T., Iida, Y., et al. Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy. Heart Vessels 29 (2014), 784–792.
36. 36 Perazzolo Marra, M., De Lazzari, M., et al. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm 11 (2014), 856–863.
37. 37 Rodríguez-Capitán, J., García-Pinilla, J.M., Ruiz-Zamora, I., et al. Long-term prognostic value of late gadolinium enhancement in a cohort of patients with nonischemic dilated cardiomyopathy. Int J Cardiol 177 (2014), 17–19.
38. 38 Yamada, T., Hirashiki, A., Okumura, T., et al. Prognostic impact of combined late gadolinium enhancement on cardiovascular magnetic resonance and peak oxygen consumption in ambulatory patients with nonischemic dilated cardiomyopathy. J Card Fail 20 (2014), 825–832.
39. 39 Amzulescu, M.S., Rousseau, M.F., Ahn, S.A., et al. Prognostic impact of hypertrabeculation and noncompaction phenotype in dilated cardiomyopathy: a CMR study. J Am Coll Cardiol Img 8 (2015), 934–946.
40. 40 Barison, A., Del Torto, A., Chiappino, S., et al. Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown) 16 (2015), 681–687.
41. 41 Chimura, M., Kiuchi, K., Okajima, K., et al. Distribution of ventricular fibrosis associated with life threatening ventricular tachyarrhythmias in patients with nonishcemic dilated cardiomyopathy. J Cardiovasc Electrophysiol, 2015 July 29 [Epub ahead of print].
42. 42 Piers, S.R., Everaerts, K., van der Geest, R.J., et al. Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm 12 (2015), 2106–2114.
43. 43 Tachi, M., Amano, Y., Inui, K., et al. Relationship of postcontrast myocardial T1 value and delayed enhancement to reduced cardiac function and serious arrhythmia in dilated cardiomyopathy with left ventricular ejection fraction less than 35. Acta Radiol 57 (2016), 430–436.
44. 44 Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
45. 45 Duan, X., Li, J., Zhang, Q., et al. Prognostic value of late gadolinium enhancement in dilated cardiomyopathy patients: a meta-analysis. Clin Radiol 70 (2015), 999–1008.
46. 46 Kuruvilla, S., Adenaw, N., Katwal, A.B., Lipinski, M.J., Kramer, C.M., Salerno, M., Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 7 (2014), 250–258.
47. 47 Stecker, E.C., Vickers, C., Waltz, J., et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 47 (2006), 1161–1166.
48. 48 Chen, Z., Sohal, M., Sammut, E., et al. Focal but not diffuse myocardial fibrosis burden quantification using cardiac magnetic resonance imaging predicts left ventricular reverse modeling following cardiac resynchronization therapy. J Cardiovasc Electrophysiol 27 (2016), 203–209.
49. 49 Ruwald, M.H., Solomon, S.D., Foster, E., et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 130 (2014), 2278–2286.
50. 50 Puntmann, V.O., Carr-White, G., Jabbour, A., et al., for the International T1 Multicentre CMR Outcome Study. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. J Am Coll Cardiol Img 9 (2016), 40–50.
51. 51 Moss, A.J., Schuger, C., Beck, C.A., et al., for the MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 367 (2012), 2275–2283.